Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life...
-
OTC:LMMY Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified Urological Surgeon. With more than five decades of experience in drug research.
-
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEOLaigo Bio’s SureTAC™ membrane protein degradation technology targets...
-
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price...
-
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price...
-
Larkspur Biosciences announced the first participant has been dosed in the Phase 1 clinical study of its lead candidate, LRK-4189, in healthy volunteers.
-
Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across...
-
Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shapeBrings over 15 years...
-
LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction.
-
LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction.